Trials Centre News Today

IN FOCUS: As a new report suggests that progress in survival rates is the slowest it’s been for 50 years in the UK, Helen Coffey dives into what went wrong – and why we’re not keeping pace with the rest of Europe

The meta-analysis of 3,292 infants across 21 studies found that premature babies whose umbilical cords are clamped 30 seconds or more after birth are less likely to die before leaving the hospital, compared to those whose cord is clamped immediately after birth.

Waiting for two minutes or longer to clamp the umbilical cord of a premature baby soon after birth could help reduce the risk of death, compared with immediately clamping the umbilical cord, or waiting a shorter time before doing so.

Waiting for two minutes or longer to clamp the umbilical cord of a premature baby soon after birth could help reduce the risk of death by more than half, compared with immediately clamping the umbilical cord, or waiting a shorter time before ...

Delaying the clamping allows blood to flow from the placenta to the baby while the babys lungs fill with air.

A course of treatment with existing drugs prior to chemoradiation led to a 35% reduction in the risk of death or return of cancer, in trial results presented by researchers from UCL and UCLH.

The INTERLACE phase III trial, funded by Cancer Research UK and UCL Cancer Trials Centre, assessed whether a short course of induction chemotherapy (IC) prior to chemoradiation (CRT) could reduce the rate of relapse and death among patients with locally advanced cervical cancer.

<p>A course of treatment with existing drugs prior to chemoradiation led to a 35% reduction in the risk of death or return of cancer, in trial results presented by researchers from UCL and UCLH at the<strong> </strong>European Society for Medical Oncology (ESMO) Congress 2023.</p>

<p>A course of treatment with existing drugs prior to chemoradiation led to a 35% reduction in the risk of death or return of cancer, in trial results presented by researchers from UCL and UCLH at the<strong> </strong>European Society for Medical Oncology (ESMO) Congress 2023.</p>

/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that it is supporting...